Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 05, 2026 | June 09, 2026 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Director · President and CEO | January 04, 2021 | January 06, 2021 |
| Obsidian Therapeutics, Inc.OBX · Entity 4898 | Director | August 03, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05 | Direct | 13,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
IOVANCE BIOTHERAPEUTICS, INC.
Report date January 04, 2021 · Filed January 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.26 · Expires 2031-01-04 | Direct | 250,000 |
Reported balance
After 2021-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-04 · Grant · Acquired 250,000 · Balance 250,000 F1: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
Obsidian Therapeutics, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2036-08-02 | Direct | 37,653 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 37,653 · Balance 37,653 F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 20:05 UTC | Obsidian Therapeutics, Inc. OBX · Entity 4898 | GrantStock Option (Right to Buy) · Derivative | 37,653 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001193125-26-335045 · ownership.xml · derivative · entry 1 Fardis Maria · CIK 0001559231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,653 Underlying: Common Stock · 37,653 shares Expires 2036-08-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $51.84 | $0.00 |
DisclosureSEC source: 0001193125-26-264290 · ownership.xml · derivative · entry 1 Fardis Maria · CIK 0001559231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $38.57 | $0.00 |
DisclosureSEC source: 0000950170-25-083268 · ownership.xml · derivative · entry 1 Fardis Maria · CIK 0001559231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders. Read SEC document |
| May 30, 2024 Filed May 31, 2024 20:15 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $54.06 | $0.00 |
DisclosureSEC source: 0000950170-24-067326 · ownership.xml · derivative · entry 1 Fardis Maria · CIK 0001559231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2034-05-30 F1 · derivative.exercise_date: This option was granted on May 30, 2024 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on May 31, 2024; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2025 Annual General Meeting of Shareholders. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 21:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $62.59 | $0.00 |
DisclosureSEC source: 0001209191-23-035974 · doc4.xml · derivative · entry 1 Fardis Maria · CIK 0001559231 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: This option was granted on June 8, 2023 with respect to 13,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2023; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2024 Annual General Meeting of Shareholders. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 21:37 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $71.70 | $0.00 |
DisclosureSEC source: 0001209191-22-036037 · doc4.xml · derivative · entry 1 Fardis Maria · CIK 0001559231 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Shares · 24,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: This option was granted on June 9, 2022 with respect to 24,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $46.26 | $0.00 |
DisclosureSEC source: 0001104659-21-001577 · tm211898-3_4seq1.xml · derivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 23:19 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,894 | $33.12 | $62,729.28 |
DisclosureSEC source: 0001104659-20-069097 · tm2021603d1_4.xml · nonDerivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,786 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. Read SEC document |
| May 01, 2020 Filed May 5, 2020 01:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,894 | $32.00 | $60,608.00 |
DisclosureSEC source: 0001104659-20-056429 · tm2018523-1_4.xml · nonDerivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,680 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested RSUs. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,494 | $27.94 | $41,742.36 |
DisclosureSEC source: 0001104659-20-043125 · tm2014835d1_4.xml · nonDerivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,574 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested RSUs. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $35.99 | $47,542.79 |
DisclosureSEC source: 0001104659-20-029218 · tm2011589d1_4.xml · nonDerivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,068 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested RSUs. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:31 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,302 | $22.54 | $29,347.08 |
DisclosureSEC source: 0001104659-20-011256 · tm206837-1_4.xml · nonDerivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,389 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested RSUs. Read SEC document |
| January 03, 2020 Filed Jan 8, 2020 02:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $25.54 | $0.00 |
DisclosureSEC source: 0001104659-20-002086 · tm201473d1_4.xml · derivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common stock · 500,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of the 500,000 shares shall vest on the one-year anniversary of January 3, 2020; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of January 3, 2020. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 00:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,562 | $26.68 | $41,674.16 |
DisclosureSEC source: 0001104659-20-001682 · tm201275d1_4.xml · nonDerivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,691 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested RSUs. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,894 | $22.66 | $42,918.04 |
DisclosureSEC source: 0001104659-19-070008 · tm1924459d2_4.xml · nonDerivative · entry 2 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,253 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| November 01, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,894 | $21.97 | $41,611.18 |
DisclosureSEC source: 0001104659-19-070008 · tm1924459d2_4.xml · nonDerivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,147 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| October 01, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,894 | $18.21 | $34,489.74 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 30 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,041 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| September 03, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,610 | $20.27 | $32,634.70 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 29 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,935 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| August 01, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $25.17 | $33,249.57 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 28 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,545 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| July 01, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $24.62 | $32,523.02 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 27 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,866 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| June 03, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $18.04 | $23,830.84 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 26 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,187 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| May 01, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $11.14 | $14,715.94 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 25 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,508 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| April 01, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $9.78 | $12,919.38 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 24 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,829 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $11.26 | $0.00 |
DisclosureSEC source: 0001144204-19-012581 · tv515609_4.xml · derivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common stock · 400,000 shares Expires 2019-03-04 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of the 400,000 shares shall vest on the one-year anniversary of March 4, 2019; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of March 4, 2019. Read SEC document |
| March 01, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,298 | $10.77 | $13,979.46 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 23 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,150 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| February 01, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,562 | $9.26 | $14,464.12 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 22 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,448 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| January 02, 2019 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,562 | $9.45 | $14,760.90 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 21 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,010 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| December 01, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $10.44 | $13,791.24 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 20 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,572 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| November 01, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $9.62 | $12,708.02 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 19 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,893 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| October 01, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $11.12 | $14,689.52 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 18 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,214 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| September 04, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $17.10 | $22,589.10 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 17 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,535 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| August 01, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $13.70 | $18,097.70 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 16 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,856 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| July 01, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $12.80 | $16,908.80 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 15 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,177 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| June 01, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $14.55 | $19,220.55 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 14 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,498 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| May 01, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $14.60 | $19,286.60 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 13 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,819 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| April 01, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $16.90 | $22,324.90 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 12 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,140 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| March 01, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,321 | $18.15 | $23,976.15 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 11 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,461 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 01:18 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001250853-18-000038 · primary_doc.xml · derivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-02-08 F1 · derivative.exercise_date: Provided the Reporting Person is employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of 166,672 shares shall vest on February 9, 2019; and (ii) the remaining stock options shall vest as to 41,666 shares in eight quarterly installments over the two years following February 9, 2019. Read SEC document |
| February 01, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,525 | $16.50 | $25,162.50 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 10 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,782 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| January 01, 2018 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,562 | $8.00 | $12,496.00 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 9 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,307 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| December 01, 2017 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,994 | $8.80 | $17,547.20 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 8 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,869 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| November 01, 2017 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,994 | $7.15 | $14,257.10 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 7 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,863 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| October 01, 2017 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,993 | $7.75 | $15,445.75 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 6 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,857 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| September 01, 2017 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,994 | $6.00 | $11,964.00 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 5 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,850 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| August 01, 2017 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,993 | $5.70 | $11,360.10 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 4 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,844 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| July 01, 2017 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,994 | $7.35 | $14,655.90 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 3 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,837 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| June 01, 2017 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 143,496 | $5.45 | $782,053.20 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 2 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,831 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
| April 03, 2017 Filed Dec 5, 2019 02:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 51,673 | $7.15 | $369,461.95 |
DisclosureSEC source: 0001104659-19-070006 · tm1924459d1_4.xml · nonDerivative · entry 1 Fardis Maria · CIK 0001559231 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498,327 F1 · shares: Exempt transaction pursuant to Section 16(b) and the rules thereunder. All of the shares reported as disposed of in this Form 4 were automatically withheld by the Issuer in accordance with the terms of the grant of the Restricted Stock Units ("RSUs") dated June 1, 2016, to satisfy federal and state tax withholding and payment obligations resulting from the vesting and settlement of RSUs. The Reporting Person did not receive or sell any of the shares reported on this Form 4 item; these shares were withheld and subsequently canceled by the Issuer in accordance with the foregoing. The grant of the RSUs was previously reported in Table I of the Reporting Person's initial Form 4 reporting the acquisition of common stock pursuant to the June 1, 2016 grant. F2 · balance_after: Shares reported include unvested Restricted Stock Units ("RSUs"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.